SC
EW icon

Sophrosyne Capital’s Edwards Lifesciences EW Stock Holding History

Sophrosyne Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-42,000
Closed -$519K – 67
2014
Q1 		$519K Buy
+42,000
New +$485K 0.45% 41

Other funds holding EW

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sophrosyne Capital's EW Position: Q2 2014 in Review

Sophrosyne Capital sold out of Edwards Lifesciences (EW) in Q2 2014, closing a stake of 42,000 shares — an estimated $519K sold.

Sophrosyne Capital first reported a position in EW in Q1 2014 and held it in 1 quarter. The position peaked at $519K in Q1 2014. 428 funds tracked by Wall St. Rank hold EW as of Q2 2014.

  • Sophrosyne Capital reported no remaining Edwards Lifesciences position as of Q2 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 42,000 Edwards Lifesciences shares in Q2 2014, an estimated $519K.
  • Sophrosyne Capital first reported a position in Edwards Lifesciences in Q1 2014 and held it in 1 quarter.
  • Sophrosyne Capital's Edwards Lifesciences position peaked at $519K in Q1 2014.
  • 428 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.